TINA K. GARYANTES, PhD

** ******* ****

Warren, NJ 07059

908-***-**** svsrkz@r.postjobfree.com

SUMMARY

Pioneering, results oriented, scientific leader in applied biology with 15+ years of contributions to pharmaceutical development candidates, medical diagnostics and biotech. Demonstrated ability to innovate and rapidly become a leader in new scientific fields. Broad portfolio knowledge across therapeutic areas and scientific disciplines from early discovery to Phase IIb.

• Led global department of 116 through transition from HTS to Lead Discovery post-merger

• Invented, developed and out-licensed well-less 1 l 1536 well-plate to Becton Dickenson

• Championed multimillion dollar collaboration and proactively mitigated risks prior to delivery

• Designed and installed, at the Mayo Clinic, the first instrument for DNA fine structure analysis

AWARDS and ADVISORY POSITIONS

Outstanding Women in Biomedical Research Award from the NJBRA (2008)

PerkinElmer International Life Sciences Award for Innovation in HTS (2002)

Scientific Advisory Board (SAB) Cytonome (2001-2007)

SAB, Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital (2008-2011)

Board Member of the Society for Biomolecular Sciences (2004-2008)

Governmental advisor to NCI, NIMH, NIH roadmap, and the NTP

Advisor to Corning Corp., Matrical, Becton Dickenson, Curinox, Berkeley Lights, and iProgen

STRATEGY LEADERSHIP BUSINESS

• Creating and communicating a vision of the future

• Anticipating and managing change

• Deep understanding of the customer • Creating a stable, appealing work environment

• Leading by example

• Breaking down silos • Assessing technical feasibility and commercial potential

• Collaboration and contract negotiations

• Technical marketing

SELECTED AREAS OF TECHNICAL EXPERTISE

Biology

In vitro assays including ADMET, ion channels, synthetases, GPCRs, kinases, PPIs, antibodies, etc.

Image based and phenotypic screening and deorphanning including primary and stem cells

Drug target assessment and progression planning for small molecules and biologics

Engineering

Biomaterials and material interfaces including microfluidics and micromachining

Imaging and light detection / detectors and microscopy

Instrumentation/automation development and testing including programming

EDUCATION

PhD, Biophysics, Caltech, Pasadena, CA 1992

BSE, Bioengineering, General Honors Degree, University of Pennsylvania, Philadelphia, PA 1983

TINA K. GARYANTES, PhD Page 2

908-***-**** svsrkz@r.postjobfree.com

PROFESSIONAL EXPERIENCE

BUSINESS/SCIENTIFIC CONSULTING 2012 – Present

Curiox, Berkeley Lights, iProgen, Venenum, Phoenix Marketing

• Enhanced marketing strategy and conducted market research including new lead development

• Interpreting clinical and medical experts

• Expanded and strengthened patent applications

• Technical consulting on engineering, assays and therapeutic target selection

• Presented technology at scientific meeting in context of cardiac toxicity predictions

• Co-writing chapter on HCS for an NIH sponsored ebook on assay development

• Thought Leader Panel Member for the annual LRIG meeting

SANOFI (including predecessor companies), Bridgewater, NJ 2000 – 2012

Head of Metabolite Biotech (2011-2012)

Selected to head new scientific business unit that developed and implemented strategies for high throughput production of metabolites, while retaining most previous responsibilities. Team included scientific computing, chemistry, mass spectroscopy, in vitro biology and global data management.

• Produced active metabolites or pharmacologically important products for three projects

• Developed HT chemistry and analytical methods to synthesize compounds that would be difficult or slow to make by traditional medicinal chemistry or combinatorial chemistry

• Established and co-chaired site-wide project progression committee to insure resource alignment and scientific quality during leadership vacuum

• Improved HCS workflow to allow third party image analysis and >5x time savings

• Globally communicated strategy for phenotypic screening and compound deorphanning

Global Head of Phenotypic and Image Based Screening and Fibrosis and Wound Repair Therapeutic Strategy Unit Business Coordinator (2010-2012)

Ensured all projects in the Fibrosis & Wound Repair therapeutic unit were successfully supported from target identification into clinical trials by a department of 2000 associates spread over 13 sites in 6 countries.

• Established phenotypic screening best practices that typically identify mechanism of action for >50% of compounds at the end of the screen and fostered a fivefold growth in the phenotypic portfolio

• Reduced image analysis time >10x through successful three way collaboration with GeneData and ThermoFisher

• Established methods for screening physiologically relevant assays with multiple endpoints and with stem cells and primary human and animal cells

• Diversified in vitro team to establish and support acute in vivo models

• Selected to participate on Oncology target identification and validation team

• Sponsored two HCS IT initiatives that improved productivity several fold

Global Head of Assay Development and Screening (2007-2009)

Directed a global team of 116 associates spread over 5 sites in 3 countries that developed and screened all primary assays including counterscreens, secondary assays and backscreens for therapeutic departments.

• Successfully shifted team from a numbers focus to an outcome focus that garnered the confidence of the therapeutic teams such that they shifted all screening to my team

• Led team responsible for reviewing and approving all new project plans (>100/year) from all therapeutic areas

• Responsible for or key contributor to global teams setting or influencing scientific direction for protein-protein interaction projects, assay quality improvements, early ADMET testing, screening outcome analysis and singleton follow up, among others

TINA K. GARYANTES, PhD Page 3

908-***-**** svsrkz@r.postjobfree.com

US Head of Lead Identification Technologies (2000-2007)

Achieved four promotions and moved from Automation Head to HTS Head to US HTS Head to US LIT Head with the addition of assay development, high throughput early ADMET, the chemical library, protein production and profiling.

• Revamped approach to HTS to increase success of projects moving from screening to Lead from near zero to 90%, resulting in 80% of the site portfolio being derived from HTS

• Redefined interactions with other departments from a service to a partnership orientation

• Increased number of proteins produced by over 50% while improving quality

• Retained entire US 40-member department during Sanofi merger with Aventis

• Member of site-wide Scientific Review Committee that progressed projects through research to phase IIb

• Created and ran global Assay Quality Workshop

• Received three special achievement awards for drug candidates

• Established collaborations that produced instrumentation for high throughput rubidium efflux assays and automated cell culture

MERCK & CO., Rahway, NJ 1996 – 2000

Research Fellow, Chemistry and Combinatorial Chemistry

• Conceived, developed, patented and out-licensed extremely flexible 1 l 1536 “virtual well” plates to Becton Dickenson for commercialization. Enabling 1 l imaging assays with rare cells, cost effective assays with rare reagents, washing, etc.

• Created companywide Technology Symposium, which has endured to present

• One of four team members that evaluated, negotiated, and helped implement multimillion dollar collaboration with Aurora Biosciences. Identified and mitigated major collaboration risks prior to installation

• Member of technology review committee with an annual budget of >$1,000,000

• Adjusted scintillation proximity assays to enable automation

CHIRON/CIBA CORNING DIAGNOSTICS, Walpole, MA 1992 – 1996

Senior Scientist promoted twice to Group Leader, Systems Development and then Staff Scientist with technical and project management responsibility for twelve scientist/engineers

• Developed and delivered first clinical instrument to the Mayo Clinic for fine structure analysis of DNA with >99% specificity and sensitivity

• Realized 50% performance improvement while converting manual assays to automation

CRYOPHARM, Pasadena, CA (during graduate school) 1990 – 1991

Group Leader of Process Development supervising five person engineering and research department studying biophysical effects of freeze-drying red blood cells

• Developed working lyophilization cycles for four diverse cellular blood products

• Designed and built a clean room

• Researched and wrote feasibility study for new immune-diagnostic product lines

Contact this candidate